Business Description
Beta Bionics Inc
NAICS : 339112
SIC : 5047
ISIN : US08659B1026
Total Employee Number:
423Description
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 27.72 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 13.09 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 644.3 | |||||
3-Year EBITDA Growth Rate | 6.1 | |||||
3-Year EPS without NRI Growth Rate | 11.3 | |||||
3-Year FCF Growth Rate | 11.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 35.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 65.37 | |||||
9-Day RSI | 65.35 | |||||
14-Day RSI | 63.63 | |||||
3-1 Month Momentum % | 37.49 | |||||
6-1 Month Momentum % | 26.6 | |||||
12-1 Month Momentum % | -15.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.88 | |||||
Quick Ratio | 7.96 | |||||
Cash Ratio | 6.94 | |||||
Days Inventory | 157.54 | |||||
Days Sales Outstanding | 45.3 | |||||
Days Payable | 30.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.2 | |||||
Shareholder Yield % | -0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.32 | |||||
Operating Margin % | -69.75 | |||||
Net Margin % | -61.32 | |||||
EBITDA Margin % | -64.89 | |||||
FCF Margin % | -51.6 | |||||
OCF Margin % | -46.89 | |||||
ROE % | -25.85 | |||||
ROA % | -23.01 | |||||
ROIC % | -95.16 | |||||
3-Year ROIIC % | -7.02 | |||||
ROC (Joel Greenblatt) % | -222.83 | |||||
ROCE % | -26.99 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 7.23 | |||||
PB Ratio | 3.42 | |||||
Price-to-Tangible-Book | 3.42 | |||||
EV-to-EBIT | -8.92 | |||||
EV-to-EBITDA | -9.1 | |||||
EV-to-Revenue | 5.91 | |||||
EV-to-Forward-Revenue | 2.1 | |||||
EV-to-FCF | -11.45 | |||||
| Price-to-Net-Current-Asset-Value | 4.49 | |||||
| Price-to-Net-Cash | 6.07 | |||||
Earnings Yield (Greenblatt) % | -11.21 | |||||
FCF Yield % | -7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BBNX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beta Bionics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 119.013 | ||
| EPS (TTM) ($) | -1.65 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 86.09 | ||
| 14-Day RSI | 63.63 | ||
| 14-Day ATR ($) | 1.167252 | ||
| 20-Day SMA ($) | 17.2365 | ||
| 12-1 Month Momentum % | -15.71 | ||
| 52-Week Range ($) | 8.8 - 32.71 | ||
| Shares Outstanding (Mil) | 44.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beta Bionics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beta Bionics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-24 | In 180 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-17 16:30 | In 174 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-17 | In 173 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-28 16:30 | In 62 days | ||
| Third quarter earnings results for 2026 | 2026-10-28 | In 61 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 16:30 | 15.80 (-3.01%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 15.80 (-3.01%) | ||
| General meeting for 2025 | 2026-05-21 14:00 | 10.11 (+7.55%) | ||
| America Securities Health Care Conference | 2026-05-12 14:20 | 9.85 (+2.39%) | ||
| First quarter earnings conference call for 2026 | 2026-04-21 16:30 | 12.91 (-1.45%) |
Show
Entries
Beta Bionics Inc Frequently Asked Questions
What is Beta Bionics Inc(BBNX)'s stock price today?
The current price of BBNX is $19.50. The 52 week high of BBNX is $32.71 and 52 week low is $8.80.
When is next earnings date of Beta Bionics Inc(BBNX)?
The next earnings date of Beta Bionics Inc(BBNX) is 2026-10-28 Est..
Does Beta Bionics Inc(BBNX) pay dividends? If so, how much?
Beta Bionics Inc(BBNX) does not pay dividend.
Press Release
Articles on Beta Bionics Inc
Robert Bruce's Top Second Quarter 2026 Move: Trimming Vicor Corp at a -0.78% Portfolio Impact
Aug 14, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers